Association between age at type 1 diabetes diagnosis and metabolic outcome at young adulthood: a real‐life observational study

2020 ◽  
Author(s):  
Tomer Goldberg ◽  
Avivit Brener ◽  
Sigal Levy ◽  
Hagar Interator ◽  
Irina Laurian ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Observational Study ◽  
Young Adulthood ◽  
Real Life ◽  
Diabetes Diagnosis ◽  
Metabolic Outcome

1066-P: Improvement in Time-in-Range (TIR) with Real-Life Use of Hybrid Closed-Loop System in Patients with Type 1 Diabetes (T1D)

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1066-P
Author(s):  
HALIS K. AKTURK ◽  
DOMINIQUE A. GIORDANO ◽  
HAL JOSEPH ◽  
SATISH K. GARG ◽  
JANET K. SNELL-BERGEON
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Real Life ◽  
Loop System ◽  
Closed Loop System ◽  
Time In Range

1316-P: Celiac Disease in Youth with Type 1 Diabetes: Association with Age at Diabetes Diagnosis

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1316-P
Author(s):  
ERIN ALVING ◽  
KRISTEN CARLIN ◽  
DALE LEE ◽  
ALISSA J. ROBERTS ◽  
JANE DICKERSON ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Celiac Disease ◽  
Diabetes Diagnosis

2066-P: Improvement of Hepatic Steatosis Index in Patients with Type 1 Diabetes and Obesity after Intensive Lifestyle Intervention: A One-Year Matched-Cohort Observational Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2066-P
Author(s):  
SHAHEEN TOMAH ◽  
MHD WAEL TASABEHJI ◽  
FAYEZ GHAZI ◽  
TAREQ SALAH ◽  
HONGXIA ZHANG ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Observational Study ◽  
Hepatic Steatosis ◽  
Lifestyle Intervention ◽  
Matched Cohort ◽  
Intensive Lifestyle Intervention ◽  
One Year ◽  
Hepatic Steatosis Index ◽  
Diabetes And Obesity

66-LB: Greater Time Spent in Hypoglycemia during Night Compared with Day during Intensified Training in Professional Cyclists with Type 1 Diabetes—A Prospective Observational Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 66-LB ◽  
Author(s):  
OTHMAR MOSER ◽  
MAX L. ECKSTEIN ◽  
OLIVIA MCCARTHY ◽  
MICHAEL RIDDELL ◽  
FEDERICO Y. FONTANA ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Observational Study ◽  
Prospective Observational Study

Effectiveness of a closed‐loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: a prospective multicenter real‐life study

2021 ◽  
Author(s):  
Valentino Cherubini ◽  
Ivana Rabbone ◽  
Maria Giulia Berioli ◽  
Sara Giorda ◽  
Donatella Lo Presti ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Real Life ◽  
Closed Loop Control ◽  
Loop Control ◽  
Life Study ◽  
Closed Loop Control System ◽  
Loop Control System ◽  
Real Life Study

scholarly journals DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life

Diabetologia ◽  
2021 ◽  
Author(s):  
Nicholas J. Thomas ◽  
John M. Dennis ◽  
Seth A. Sharp ◽  
Akaal Kaur ◽  
Shivani Misra ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Major Type ◽  
Diabetes Incidence ◽  
Diabetes Diagnosis ◽  
Risk Haplotype ◽  
Adult Onset ◽  
Uk Biobank ◽  
Onset Type ◽  
Increased Risk

Abstract Aims/hypothesis Among white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased. Methods In two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0–18 years, 19–30 years and 31–50 years. Results DR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, all p < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5–18 years OR 0.16 (95% CI 0.08, 0.31); age 19–30 years OR 0.10 (0.04, 0.23); and age 31–50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes. Conclusions/interpretation HLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life. Graphical abstract

scholarly journals Sleep quality and glycaemic variability in a real-life setting in adults with type 1 diabetes

Diabetologia ◽  
2021 ◽  
Author(s):  
Rachel Brandt ◽  
Minsun Park ◽  
Kristen Wroblewski ◽  
Lauretta Quinn ◽  
Esra Tasali ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Sleep Quality ◽  
Real Life ◽  
Glycaemic Variability ◽  
Real Life Setting

Prevalence of autoantibodies in type 1 diabetes mellitus pediatrics in Mazandaran, North of Iran

2020 ◽  
Vol 33 (10) ◽  
pp. 1299-1305
Author(s):  
Daniel Zamanfar ◽  
Mohsen Aarabi ◽  
Monireh Amini ◽  
Mahila Monajati
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Serum Level ◽  
Type 1 Diabetes Mellitus ◽  
Children And Adolescents ◽  
Statistical Significance ◽  
Pancreatic Beta Cell ◽  
Eligible Patient ◽  
Diabetes Diagnosis

AbstractObjectivesType 1 diabetes is an autoimmune disease. Its most important immunologic markers are pancreatic beta-cell autoantibodies. This study aimed to determine diabetes mellitus antibodies frequency among children and adolescents with type 1 diabetes.MethodsThis descriptive study evaluated the frequency of four diabetes autoantibodies (glutamic acid decarboxylase 65 autoantibodies [GADA], islet cell autoantibodies [ICA], insulin autoantibodies [IAA], tyrosine phosphatase–like insulinoma antigen-2 antibodies [IA-2A]) and their serum level in children and adolescents diagnosed with type 1 diabetes mellitus at the diabetes department of Bou-Ali-Sina Hospital and Baghban Clinic, Sari, Iran, from March 2012 to March 2018. The relationship between the level of different antibodies and age, gender, and diabetes duration were determined. A two-sided p value less than 0.05 indicated statistical significance.ResultsOne hundred forty-two eligible patient records were screened. The average age at diabetes diagnosis was 4.2 ± 4.4 years. The median duration of diabetes was 34.0 (12.7–69.7) months. 53.5% of patients were female, and 81.7% of them had at least one positive autoantibody, and ICA in 66.2%, GADA in 56.3%, IA-2A in 40.1%, and IAA in 21.8% were positive. The type of the autoantibodies and their serum level was similar between females and males but there was a higher rate of positive autoantibodies in females. The level of IA-2A and ICA were in positive and weak correlation with age at diagnosis.ConclusionsMore than 80% of pediatric and adolescent patients with type 1 diabetes were autoantibody-positive. ICA and GADA were the most frequently detected autoantibodies. The presence of antibodies was significantly higher in females.

scholarly journals Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Emma S. Scott ◽  
Andrzej S. Januszewski ◽  
Luke M. Carroll ◽  
Gregory R. Fulcher ◽  
Mugdha V. Joglekar ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Diabetes Diagnosis ◽  
Subcutaneous Insulin ◽  
Glycaemic Variability ◽  
Altered Expression ◽  
C Peptide

AbstractTo determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519–563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. − 2.2 ± − 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.

Sign in / Sign up

Export Citation Format

Share Document